

Edgar Filing: Wheeler Real Estate Investment Trust, Inc. - Form 8-K

Wheeler Real Estate Investment Trust, Inc.
Form 8-K
June 03, 2015

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES AND EXCHANGE ACT OF 1934
Date of report (date of earliest event reported): June 3, 2015

WHEELER REAL ESTATE INVESTMENT TRUST, INC.
(Exact name of registrant as specified in its charter)

Maryland (State or Other Jurisdiction of Incorporation) 2529 Virginia Beach Blvd., Suite 200 Virginia Beach, VA 23452 Registrant's telephone number, including area code: (757) 627-9088	001-35713 (Commission File Number)	45-2681082 (IRS Employer Identification No.)
---	--	--

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 8.01 OTHER EVENTS.

On June 3, 2015, the Registrant issued a press release announcing the Registrant's Chief Executive Officer, Jon Wheeler, is scheduled to present at the REITWeek 2015: NAREIT's Investor Forum in New York, New York on Wednesday, June 10, 2015 at 2 PM Eastern Time. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(a) Financial statement of businesses acquired.

Not applicable.

(b) Pro forma financial information.

Not applicable.

(c) Shell company transactions.

Not Applicable.

(d) Exhibits.

99.1 Press release dated June 3, 2015, announcing the Registrant's Chief Executive Officer, Jon Wheeler, is scheduled to present at the REITWeek 2015: NAREIT's Investor Forum in New York, New York on Wednesday, June 10, 2015.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

WHEELER REAL ESTATE INVESTMENT TRUST, INC.

By: /s/ Jon S. Wheeler
Jon S. Wheeler
Chairman and Chief Executive Officer

Dated: June 3, 2015

EXHIBIT INDEX

Number	Description of Exhibit
99.1	Press release dated June 3, 2015, announcing the Registrant's Chief Executive Officer, Jon Wheeler, is scheduled to present at the REITWeek 2015: NAREIT's Investor Forum in New York, New York on Wednesday, June 10, 2015.

0); border-right: 1px solid rgb(0, 0, 0);">

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2016-10-13

f)

Place of the transaction

n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr S A Hussain

President, Global

b) Position/status Pharmaceuticals

c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

b) Nature of the transaction

c) Price(s) and volume(s) Price(s) Volume(s)

£16.9675 223.598

d) Aggregated information n/a (single transaction)

Edgar Filing: Wheeler Real Estate Investment Trust, Inc. - Form 8-K

- Aggregated volume Price
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr B McNamara
- b) Position/status CEO, GSK Consumer Healthcare
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|-----------|-----------|
| \$42.0900 | 284.061 |
- d) Aggregated information Aggregated volume Price n/a (single transaction)
- e) Date of the transaction 2016-10-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

	ISIN: GB0009252882	
	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.	
b) Nature of the transaction		
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.9675	178.878
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2016-10-13	
f) Place of the transaction	n/a	

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Ms C Thomas
b) Position/status	Senior Vice President, Human Resources

c) Initial notification/ amendment	Initial notification
------------------------------------	----------------------

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.	
b) Nature of the transaction		
c) Price(s) and volume(s)	Price(s)	Volume(s)
	£16.9675	178.878
d) Aggregated information	n/a (single transaction)	
e) Date of the transaction	2016-10-13	
f) Place of the transaction	n/a	

Edgar Filing: Wheeler Real Estate Investment Trust, Inc. - Form 8-K

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Dr P J T Vallance
 - b) Position/status President, Pharmaceuticals R&D
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to
 - b) Nature of the transaction shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.9675	223.598
 - d) Aggregated information aggregated volume Price n/a (single transaction)
 - e) Date of the transaction 2016-10-13
 - f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: October 17, 2016

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc